FDA Regulatory partner, George O’Brien will discuss “Hot Topics in Patents including Orange Book Cases & Patent Eligibility” on October 8 at this year’s Pharma Law USA conference in Boston presented by Informa. The panel will address:
- Review of FTC’s notice for Orange Book patent violations
- Cooperation between FTC, FDA and Patent and Trademark Office
- How should patents be managed and granted?
- Is there an alternate way to force more generic substitution?
- Patent eligibility: lessons learnt from Regeneron Vs Kymab and Revised Patent Subject Matter Eligibility Guidance
- FDA’s 30-month preliminary injunctions: can they result in anti-trust violations?
For more information and to register, please visit the event webpage.
